Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome
Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome
复制标题
DOI：
10.2217/fon.14.14
复制
发表时间：
2014-04-01
期刊：
影响因子：
3.3
通讯作者：
Abernethy, Amy P.
中科院分区：
文献类型：
--
作者：
Currow, David C.;Abernethy, Amy P.
盐酸阿拉莫林是Helsinn开发的一种口服活性胃饥饿素受体激动剂，用于治疗非小细胞肺癌（NSCLC）恶病质。在临床前和临床研究中，与安慰剂相比，阿拉莫林对胃饥饿素受体的有效亲和力与显著的食欲增强活性和由此产生的体重、瘦体重和握力的改善相关。伴随的对生长激素和IGF-1的刺激作用与肿瘤生长无关，并且癌症患者的总生存期不受影响。阿拉莫林耐受性良好，迄今为止未发现剂量限制性毒性。需要正在进行的III期研究的结果来证实阿拉莫林治疗NSCLC恶病质的显著潜力。
Anamorelin hydrochloride is an orally active ghrelin receptor agonist in development by Helsinn, for the treatment of non-small-cell lung cancer (NSCLC) cachexia. In preclinical and clinical studies, the potent affinity of anamorelin for the ghrelin receptor is associated with significant appetite-enhancing activity and resultant improvements in body weight, lean body mass, and handgrip strength compared with placebo. The accompanying stimulatory effects on growth hormone and IGF-1 are not associated with tumor growth, and overall survival in patients with cancer is not compromised. Anamorelin is well tolerated with no dose-limiting toxicities identified to date. The findings of ongoing Phase III studies are needed to confirm the significant potential of anamorelin to treat NSCLC cachexia.